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Abstract
Context: Management of bladder cancer (BC) is primarily driven by stage, grade, and biological potential. Knowledge
of each is derived using clinical, histopathological, and radiological investigations. This multimodal approach reduces
the risk of error from one particular test, but may present a staging dilemmawhen results conflict. Multiparametric
magnetic resonance imaging (mpMRI) may improve patient care through imaging of the bladder with better
resolution of the tissue planes than computed tomography and without radiation exposure.
Objective: Todefinea standardized approach to imaging and reportingmpMRI for BC, bydeveloping aVI-RADS score.
Evidence acquisition: We created VI-RADS (Vesical Imaging-Reporting And Data System) through consensus
using existing literature.
Evidence synthesis: We describe standard imaging protocols and reporting criteria (including size, location,
multiplicity, and morphology) for bladder mpMRI. We propose a five-point VI-RADS score, derived using T2-
weighted MRI, diffusion-weighted imaging, and dynamic contrast enhancement, which suggests the risks of
muscle invasion. We include sample images used to understand VI-RADS.
Conclusions: We hope that VI-RADS will standardize reporting, facilitate comparisons between patients, and in
future years, will be tested and refined if necessary. While we do not advocate mpMRI for all patients with BC,
this imagingmaycompliment pathology or reduce radiation-based imaging. BladdermpMRImay bemost useful
in patients with non–muscle-invasive cancers, in expediting radical treatment or for determining response to
bladder-sparing approaches.
Patient summary: Magnetic resonance imaging (MRI) scans for bladder cancer are becomingmore common and
may provide accurate information that helps improve patient care. Here, we describe a standardized reporting
criterion for bladder MRI. This should improve communication between doctors and allow better comparisons
between patients.
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Bladder cancer (BC) is one of the most common and
expensive human malignancies to manage [1–3]. Most BCs
are urothelial cell carcinomas (UCCs), and histologically
stratified into cancers with low and high grade [4]. The
latter are subdivided into those with and without muscle
invasion. Non–muscle-invasive BCs (NMIBCs) are often low
grade and have an indolent natural history [5]. Treatment is
aimed at reducing local recurrence and stage progression,
and maintaining quality of life [6]. High-grade lesions
represent around one-third of NMIBCs, and can progress to
muscle invasion and metastases in around 20–25% patients
[7–9]. Treatment aims to reduce stage progression and
preserve quality of life, whilemaintaining close surveillance
to detect the onset of muscle invasion. Muscle-invasive BCs
(MIBCs) are aggressive tumors with an ominous prognosis
[10]. Success of treatment is dependent on the stage of the
primary tumor and status of the regional lymph nodes. Cure
can be achieved in 75–80% of patients with organ-confined
disease, 60% of those with T3 node–negative disease and
30% with lymph node–positive disease [11–15]. Despite
increasing use of systemic therapy, overall survival rates
fromBC have not improved over the last 30 yr [16] and these
patients have some of the lowest healthcare experience
ratings [17].
1.2. Transurethral resection
BC is usually detected by flexible cystoscopy following an
episode of hematuria or for mixed urinary symptoms
[6]. The diagnosis of BC is made by transurethral resection
of bladder tumor (TURBT) of all or the most exophytic/
intraluminal tumor component. TURBT is used as defini-
tive treatment for most NMIBCs and serves as a diagnostic
procedure for most MIBCs. A properly performed TURBT
samples the underlying bladder wall including the
muscularis propria. Understaging occurs with TURBT,
and it may miss muscle infiltration in up to 25% of
invasive cancers [18–20]. TURBT is operator dependent,
and so residual tumor rates (reflecting incomplete BC
resection) varywidelywith experience [9,21]. Re-resection
of the bladder is advised in high-risk NMI cancers, prior to
bladder preserving chemoradiation, or where the clinical
and pathological findings differ [6,22,23]. Recent techno-
logical advances, such as narrow band imaging or the use
of fluorescence agents (“blue light cystoscopy”), may
improve the outcomes from TURBT [24,25]. While TURBT
is the mainstay of diagnosis that has been used safely since
the 1950s, there are concerns that it could lead to cancer
embolization [26] and the oncological risks of perforation
remain unknown [27].
1.3. Radiological staging of BC
The prognosis and management of BC mostly reflects
tumor stage. For the primary tumor, this includes depth ofinvasion into the lamina propria, detrusor muscle,
perivesical fat, adjacent organs, or pelvic side wall
[28]. For metastases, this includes regional lymph nodes
(number and location) and the presence of distant
metastases. BC staging is accomplished through the
combination of clinical (examination), pathological
(TURBT specimens), and radiological means. Radiological
examination should look for second urinary tract malig-
nancies (5% of BCs may have an upper tract UCC) or other
pathologies. Most guidelines suggest cross-sectional im-
aging for MIBCs and high-grade NMI cancers, due to the
risks of invasion and regional or distant metastases, and
upper urinary tract involvement.
1.4. Potential role of mpMRI in BC care
The multimodal approach to BC staging reduces the risk of
error from one particular test, but may present a staging
dilemmawhen results conflict [29,30]. Despite their apparent
rigor, each modality is operator dependant and the concor-
dance between individuals varies widely. For example, the
quality of the TURBT will vary among surgeons, pathologists
may disagree in BC grading (10–29% discordance) and staging
(15–56% discordance) [4,31], while radiologists differ in
agreement about muscle invasion [32]. Multi-parametric
magnetic resonance imaging (mpMRI) offers an opportunity
to reduce staging errors through better anatomical visualiza-
tion [33,34]. Given its lack of radiation, mpMRI also offers a
potentially safer tool to investigate individuals at risk of BC
and to image the same patients prior to, during, and following
treatment to determine response.2. Evidence acquisition
2.1. Materials and methods
VI-RADS started with a nonsystematic literature review
using Medline, PubMed, and Web of Science in July
2017. Search terms included “bladder cancer”, “urothelial
carcinoma”, “MRI,” and “multi-parametric MRI.” This fed
organization of the subtopics and informed literature
selection. The VI-RADS system was achieved through a
Delphi-like consensus using multidisciplinary team mem-
bers from Europe, North and South America, and Asia, in a
combination of electronic and face-to-face rounds.1. Panel members were asked to summarize the evidence
in the given area and highlight areas of controversy.
Members of the working group met in Chicago in
November 2017 (RSNA meeting) to agree with the
statements. A facilitator collated the proposals.2. Members of the working group evaluated each proposal,
based on evidence-based research and professional expe-
rience, before drafting VI-RADS and deriving consensus.3. The manuscript was written by subteams for each topic,
through a series of iterations before final voting by the
entire working group on the final content.
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were solved through experience and prior literature.
3. Evidence synthesis
3.1. Technical considerations for image acquisition
3.1.1. Clinical considerations
3.1.1.1. Timing of MRI and bladder treatments. Previous TURBT and
intravesical Bacille Calmette-Guerin (BCG) or chemothera-
py instillation cause edema and inflammation in the
bladder wall and surrounding perivesical tissues, which
can be difficult to distinguish from BC (resulting in
overestimation of local stage) [35]. As there is no reliable
method to avoid or measure reactive change in the bladder
wall, MRI examination is best performed before or at least
2 wk after TURBT, bladder biopsy, or intravesical treatment.
Air in the bladder (from cystoscopy or indwelling catheter)
can cause distortion of diffusion-weighted imaging (DWI)
due to susceptibility artifact. A 2–3-d interval between
cystoscopy or removal of Foley catheter and MRI examina-
tion is recommended if the patient's condition allows.
3.1.1.2. Patient preparation. Motion and susceptibility artifacts
from bowel peristalsis can be minimized by the administra-
tion of an intramuscular antispasmodic agent [36]. Adequate
bladder distension allows correct visualization of the wall
and identification of the muscularis propria (detrusor)
without any folds (Supplementary Fig. 1). Adequate bladder
distention is vital and can be achieved by instructing the
patient to void 1–2 h before imaging or by instructing the
patient to start drinking 500–1000 ml of water in the 30 min
before the examination, depending on the patient's toler-
ance level [37,38]. Without distention, the bladder wall will
appear thick and uneven, leading to either a misdiagnosis of
BC or overstaging of tumors that are present. Overdistension
of the bladdermay cause amotion artifact due to discomfort,
and the extent of BC will be indistinct. In patients with a
history of incomplete bladder emptying, a residual volume
ultrasound scan prior toMRI can be useful to judgewhen the
bladder is optimally full (around 300 ml). Real-time MRI
images can also be used to determine adequate bladder
filling. For an underfilled bladder, the scan should be
repeated in 30–60 min after the patient has drunk more
fluid. In case of an overfilled bladder, the patient should
partly empty their bladder before the scan is repeated.
3.1.2. Technical considerations
3.1.2.1. MR equipment and protocol optimization. MRI (1.5 or 3.0 T)
is recommended to achieve high spatial resolution and
signal-to-noise ratio. A multichannel phased array external
surface coil is also recommended.
3.1.2.2. Image acquisition. T2-weighted (T2W) imaging, DWI,
and dynamic contrast-enhanced imaging (DCEMRI) are key
components of mpMRI examination. All images should
include the whole bladder, proximal urethra, pelvic nodes,
and prostate if the patient is a male. In females, adjacentpelvic viscera (uterus, ovaries, fallopian tubes, and vagina)
should also be included. Spin-echo T1-weighted (T1W)
imaging is used to identify hemorrhage and clot in the
bladder, and bone metastasis.
3.1.2.2.1. T2-weighted imaging. At least two planes of multi-
planar (axial, coronal, and sagittal) T2W images without fat
suppression are usually obtained with two-dimensional
(2D) fast-spin-echo (FSE) or turbo-spin-echo sequences.
Three-dimensional spin-echo acquisitions (eg, SPACE, CUBE,
VISTA) may be used as an adjunct to 2D acquisitions. If
acquired using isotropic voxels, an arbitrary plane perpen-
dicular to tumor base can be reformatted. For 2D-FSE, slice
thickness of 3–4 mm is recommended to maximize spatial
resolution while maintaining the signal-to-noise ratio.
3.1.2.2.2. Diffusion-weighted imaging. DWI is computed by
quantifying the diffusion of water molecules in tissues,
and it plays a significant role in the bladder mpMRI
examination. Axial and sagittal/coronal breathing-free spin-
echo EPI sequence combined with spectral fat saturation is
recommended. A high b value (800–1000 s/mm2) is needed
to visualize BC with high contrast to surrounding tissues;
however, a too high b value is unnecessary and it may
degrade signal-to-noise ratio [39]. It is essential to obtain
DWI with good image quality, maintaining a balance
between high spatial resolution and signal-to-noise ratio.
Consideration should be given to available tools and
techniques to achieve this, including the use of parallel
imaging with short echo time, increasing the number of
excitations, and adjusting the matrix and corresponding
voxel size (Table 1). A drawback of DWI is difficulty in
understanding the anatomical location because of the signal
suppression of the background. Therefore, locations should
match or be similar to those used for T2W imaging to
interpret DWI referencing T2W imaging [40].
3.1.2.2.3. Dynamic contrast enhanced imaging. Although either a
2D or a 3D T1 gradient echo (GRE) sequence with fat
suppression may be used, 3D acquisition (eg VIBE, LAVA,
THRIVE) is preferred to obtain higher spatial resolution
[41]. Precontrast imaging is also acquired. A gadolinium-
based contrast agent is administered using a power-injector
system at a dose of 0.1 mmol/kg of body weight at a rate of
1.5–2.0 ml/s if standard relaxivity agent is used and
followed by saline flush [42]. Initial contrast image is
acquired (midline of k-space is filled) at 30 s after the
beginning of injection and followed by the same sequences
four to six times every 30 s to depict the early enhancement
of inner layer followed by tumor enhancement [43]. If 3D-
GRE is acquired with isotropic voxels, an arbitrary plane
perpendicular to tumor base can be reformatted. Late phase
is not useful for T staging because signal contrast among the
inner and outer layers and tumor decreases.
3.1.2.2.4. Semiquantitative/quantitative measurement (optional).
Several studies are exploring quantitative measurements,
such as apparent diffusion coefficient (ADC) and perfusion
curves, to find objective markers for MRI tumor evaluation.
Table 1 – Examples of parameter setting (1.5 and 3.0 T)
T2W DWI DCE MRI
Parameter setting at 1.5 T
TR (ms) 5000 4500 3.3
TE (ms) 80 88 1.2
Flip angle (degree) 90 90 13
FOV (cm) 23 27 35
Matrix 256  189–256 128  109 256  214
Slice thickness (mm) 4 4 2
Slice gap (mm) 0–0.4 0–0.4 0
Number of excitations 1–2 10–15 1
b values 0–800–1000
Parameter setting at 3.0 T
TR (ms) 4690 2500 up to 5300 3.8
TE (ms) 119 61 1.2
Flip angle (degree) 90 90 15
FOV (cm) 23 32 27
Matrix 400  256–320 128  128 192  192
Slice thickness (mm) 3–4 3–4 1
Slice gap (mm) 0–0.4 0.3–0.4 0
Number of excitations 2–3 4–10 1
B values 0–800–1000 (up to) 2000 s/mm2
DCE = dynamic contrast enhancement; DWI = diffusion-weighted imaging; FOV = field of view; MRI = magnetic resonance imaging; TE = echo time;
TR = repetition time; T2W = T2 weighted.
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tive parameters. Three regions of interest may be consid-
ered, placed respectively on the intravesical tumor, at the
bladder wall immediately below the lesion (detrusor/tumor
interface) between the bladder mucosa and detrusor
muscle, and on a normal detrusor muscle remote from
the lesion. In low-grade tumors, the contrast washout is
higher than for high-grade cancers [44]. On perfusion
weighted imaging, the k-trans allows the evaluation of
capillary permeability, which is indirectly an expression of
tumor neoangiogenesis [45]. Greater permeability was
present in the intraluminal tumor and in the detrusor wall
for muscle-invasive cancers [46].
Several authors have reported that ADC values differ
between low, intermediate, and high histological grade
tumors, suggesting a possible correlation between imaging
and histopathology. A lack of conclusive ADC cutoff values
and different techniques applied (different b values) limits
this semiquantitative tool. Diffusion tensor imaging has
been reported, and fractional anisotropy is an objective
index that increases at the interface between the tumor and
the bladder wall in MIBC [46].
3.1.2.2.5. Example of parameter setting. Although the optimal
scan parameter depends on MRI scanner, examples of
representative parameters are shown in Table 1.
3.2. Scoring and reporting of images
3.2.1. Rationale
In VI-RADS, we aim to standardize bladder mpMRI for
clinical and research applications. In particular, we try to
create a systematic approach to reporting bladder MRI and
defining the risk of muscle invasion (NMIBC vs MIBC). The
scoring is applicable to untreated patients (uVI-RADSscoring) and to patients having received “only” diagnostic
TURBT (tVI-RADS), before re-TURBT.
3.2.2. Anatomy
3.2.2.1. Histology. The bladder wall includes three basic layers:
mucosa,muscularis propria (detrusormuscle), andperivesical
fat. The mucosa includes surface urothelium and underlying
subepithelial connective tissue (or lamina propria). Normal
urothelium is seven or fewer cells thick, hyperplastic and
dysplastic lesions can be thicker, and in carcinoma in situ
cells lose adhesion. The subepithelial connective tissue
depth is similar for the anterior, posterior, and lateral walls
(0.72–2.55 mm), but thinner at the trigone (ie, 0.46–1.58 mm)
and thicker at the dome (0.98–3.07mm) [47]. The sub-
epithelial connective tissue contains a muscularis mucosae.
This consists of wavy, thin, smooth muscle fascicles often
associated with large, thin-walled blood vessels. It can be
identified in 15–83% of biopsy specimens. Discernable
muscularis mucosae is missing in 6% radical cystectomy
specimens. In such situation, the large vessels can be used as a
surrogate marker of muscularis mucosae [47–50]. The
connective tissue between the muscularis mucosae and the
muscularis propria is occasionally called “submucosa” by
radiologists. The muscularis propria is composed of inner and
outer smooth muscles with different orientations. The
boundary between the muscularis propria and perivesical
tissue is not well defined. Aggregates of adipose tissue are
often seen in muscularis propria, and in 61% are abundant in
deep muscularis propria. The muscularis propria adipose
tissue merges with perivesical adipose tissue without a clear
line of demarcation from the perivesical tissue [48]. Tumor-
related factors such as dense fibrosis, inflammation, and
tumor cells at the edge of outermost muscularis propria can
make the distinction between muscularis propria and
perivesical tissue difficult [48].
E U RO P E AN U RO L OGY 74 ( 2 018 ) 2 9 4 – 3 0 62983.2.2.2. MRI appearances of anatomy. MRI does not have the
necessary spatial resolution to visualize all the histological
bladder wall layers (Fig. 1) [51]. Muscularis propria
(detrusor) appears as a low signal intensity (SI) line on
T2W images, while the inner layer composed of urothelium
and lamina propria is not seen. At DWI, the inner layer is not
visualized, while muscularis propria appears as an inter-
mediate SI line.With ADCmaps, urine appears hyperintense
and bladder wall is of intermediate SI. With DCE, the inner
layer presents early enhancement, and it appears as a high
SI line, while muscularis propria presents as a low SI line
that enhances slowly and progressively [42,51]. Clinicians
should be aware that several conditions can cause
inflammation of urothelium and lamina propria, resulting
in thickening and edema. In such cases, T2W images may
show a thickened hyperintense line (ie, the edematous
inner layer) that overlays the hypointense muscular layer
[51]. DWI may show a thickened hypointense line repre-
senting edematous mucosa.
3.2.2.3. MRI appearances with benign bladder pathologies. The
bladder wall structure and MRI appearance may mimic
cancer in various benign diseases and with some treat-
ments (see section 3.2 for more detail). It is therefore
important to correlate MRI findings with the clinical
history, treatments received, and cystoscopic appear-
ances. For example, cystitis cystica and cystitis glandularis
produce flat and exophytic growth patterns, with low SI on
T1WandT2W images, andhypervascular stalkswith intact
muscularis propria [47]. Inflammatory myofibroblastic
tumors (IMFs), characterized by proliferation of plump,
stellate, or elongated spindle cells with inflammatory cells
and edematous or myxoid stroma containing a delicate
network of small blood vessels, may also be misdiagnosed
as cancer. OnT2WMR images, IMFs appear heterogeneous,
with a central hyperintense component surrounded by a
low SI periphery; after administration of contrastmaterial,Fig. 1 – Schematic appearance of bladder wall anatomy and respective MRI app
low SI of muscular layer, and cannot visualize/discriminate the urothelium and
intermediate SI line, while inner layer is not visualized; ADC maps shows inter
The bladder wall components change appearance during the phases of DCE im
enhancement; DWI = diffusion-weighted imaging; MRI = magnetic resonance imthe periphery enhances while the central region enhances
poorly [47]. With regard to treatments, in the long term,
TURBTcauses fibrosis and chronic inflammation, replacing
the normal bladder wall components and often leading to
thickening of the wall. Chronic inflammatory or fibrotic
tissues have lower cellular density than cancer, so that
restriction is not so evident. Nevertheless, as they can
show early enhancement at DCE MRI, DWI and ADC are
crucial for differential diagnosis [49,50]. BCG therapy can
lead to bacterial and immune-mediated cystitis, granulo-
matous inflammation, and bladder contracture, each of
which may mimic a recurrent tumor [48]. Intravesical
chemotherapy may produce similar changes. Radiothera-
py to the pelvis (and bladder) in the short term may cause
hemorrhagic cystitis, intraluminal clots, edema, and
inflammation of the bladder. On MRI, these appear as
focal or diffuse irregular thickening, within a bladder with
decreased distensibility (low bladder volume) and hyper-
vascularity. MRI may reveal high SI of the inflamed and
edematous bladderwall at T2Wsequences [47]. In the long
term, radiation may result in interstitial fibrosis, with low
SI on T2W images [47].
3.2.3. Recording Bladder lesions
3.2.3.1. MRI definition of the lesion. Intravesical lesions with T2
SI intermediate to urine and muscle, a high DWI signal and
a low signal at ADC map, and postcontrast early enhance-
ment at DCE MRI (Fig. 1) should be recorded as suspicious
lesions.
3.2.3.2. Mapping. A schematic map is recommended to record
the tumor location (example in Fig. 2). About one-third of
new tumors arise from the trigone, bladder neck, and
ureteral orifice regions, and a slightly greater number from
the lateral walls [31]. Bladder neck cancers have a
significantly higher frequency of muscle invasion
[52]. The presence of multiple tumors should be recorded,earances at T2W imaging, DWI, ADC, and DCE MRI. T2W images show
the lamina propria. At DWI, the muscular layer appears as an
mediate signal of muscular layer compared with high signal of urine.
aging. ADC = apparent diffusion coefficient; DCE = dynamic contrast
aging; SI = signal intensity; T2W = T2 weighted.
Fig. 2 – Schematic map of the bladder modified from the Japanese Urological Association, the Japanese Society of Pathology, Japan Radiological
Society schema (published in General rule for clinical and pathological studies on renal pelvic, ureteral and bladder cancer, Kanehara Publisher
Inc., 2011, p. 16).
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or highest number) and the tumor with radiological
appearance of most advanced stage.
3.2.3.3. Morphology (size, growth pattern, stalk). Tumors may be
of endophytic (intramural growth), exophytic (endoluminar
growth), flat (nonmass effect), and mixed forms. The
exophytic form can be papillary broad based or peduncu-
lated; papillary tumors with a stalk are generally of better
prognosis that papillary tumors without a stalk or broad
sessile cancers. Stage T1 tumors with stalks (median
diameter 21.5 mm) are generally larger than those without
stalks (13 mm) at T1 stage [49,53]. A tumor average size of
21.8, 23.2, and 33.7 was found in low-, intermediate-, and
high-grade BC, respectively [44]. Small and flat BC (<1 cmof
diameter) may have no stalk, and have the same T2 SI and
enhancement pattern of the inner bladder layer. While this
can cause an overestimation, tumor burden using DCE
imaging [46], DWI, and T2W imaging help improve
accuracy.
3.2.4. MRI scoring
3.2.4.1. Scoring. We propose scoring tumors using appear-
ances in T2W imaging, DWI, and DCE to create an overall
risk of invasion score (Figs. 3 and 4, and Supplementary Fig.
2). Normal bladder mucosa/inner layer shows high T2W SI
and early phase enhancement in DCE MRI. Normal bladder
mucosa/inner layer is not seen on T2W and DWI sequences
under normal circumstances; however, these may be seenas a high SI structure on T2W images and a low SI structure
on DWI if seen due to edema or inflammation. Normal
muscularis propria shows low SI on T2W images and no
early enhancement at DCE MRI. Visualization of different
muscular layers is difficult to achieve, but can be seen as low
T2 SI of the innermost muscular layer (muscularis propria)
and intermediate intensity in the outer part [51].
3.2.4.2. Assessment for T2W imaging. Muscle appears hypoin-
tense on T2W images. This should be the first MR
appearance to search in the examination. Interruption of
the low SI muscular line may suggest muscle invasion.
Different scenarios may be present [48,49,53]:1. Structural category (SC) 1: uninterrupted low SI line
representing the integrity of muscularis propria (lesion
<1 cm; exophytic tumor with or without stalk and/or
thickened inner layer)2. SC 2: uninterrupted low SI line representing the integrity
of muscularis propria (lesion >1 cm; exophytic tumor
with stalk and/or high SI thickened inner layer, when
present, or sessile/broad-based tumor with high SI
thickened inner layer, when present)3. SC3: lack of category 2 findingswith associated presence of
an exophytic tumor without stalk, or sessile/broad-based
tumor without high SI thickened inner layer but with no
clear disruption of low SI muscularis propria4. SC 4: interruption of low SI line suggesting extension of
the intermediate SI tumor tissue to muscularis propria
Fig. 3 – Schematic illustration of mpMRI appearances of VI-RADS scores 1–5 using T2, DCE MRI, DWI, and ADC. ADC = apparent diffusion coefficient;
DCE = dynamic contrast enhancement; DWI = diffusion-weighted imaging; MRI = magnetic resonance imaging; mpMRI = multiparametric MRI;
SI = signal intensity.
Fig. 4 – Summary schematic representation of VI-RADS scoring. Scoring interpretation: for categories 1–3, the “first pass scoring” T2 sequence should
be considered. For categories 4 and 5, the dominant sequences are DWI (first, when image quality is optimal) and DCE (second). CE = contrast-
enhanced category; DCE = dynamic contrast enhancement; DW = diffusion-weighted category; DWI = diffusion-weighted imaging; SC = structural
category; SI = signal intensity.
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Table 2 – Example of VI-RADS report template
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Clinical indications:
MRI acquisition protocol:
Findings:
Mapping lesion/s: Index lesion
Morphology:
Measurements of the lesions:
Scoring:
T2W
DWI
DCEC 5: extension of intermediate SI tumor to extravesical
fat, representing the invasion of the entire bladder wall
and extravesical tissues
3.2.4.3. Assessment for DCE MRI. As for DCE MRI, tumor and
inner layer enhance early andmayenhance at the same time
and grade. Muscularis propria shouldmaintain no enhance-
ment in the early phase, and it is recognizable as a low SI
line under the tumor [44,46,48,51]. Contrast-enhanced (CE)
categories are as follows:Final VI-RADS assessment (categories):
Semi/quantitative analysis (optional)1. CTransmural extension:
E category 1: No early enhancement of the muscularis
propria (lesions corresponding to SC 1 findings)
Adjacent organ invasion:
Nodes a:2. C
Bone:
Comments:E category 2: no early enhancement of muscularis
propria with early enhancement of inner layer (lesions
corresponding to SC 2 findings)DCE = dynamic contrast enhancement; DWI = diffusion-weighted imaging;3. C
MRI = magnetic resonance imaging; T2W = T2 weighted.
a Criteria for pathological pelvic lymph nodes: (1) short axis 7.0 mm; (2)E category 3: lack of category 2 findings (lesions
corresponding to SC category 3 findings) but with no
clear disruption of low SI muscularis propriaround morphology; (3) loss of internal architecture; and (4) nodal4. C
extracapsular extension.E category 4: tumor early enhancement extends focally
to muscularis propria5. CE category 5: tumor early enhancement extends to the
entire bladder wall and to extravesical fat
3.2.4.4. Assessment for DWI/ADC. The tumor is hyperintense on
DWI and hypointense on ADC map. Muscularis propria may
present intermediate SI, while the stalk and inner layer have
low SI on DWI [51,53]:1. DW category 1: muscularis propria with intermediate
continuous SI on DWI (lesion <1 cm, hyperintense on
DWI and hypointense on ADC, with or without stalk and/
or low SI thickened inner layer on DWI)2. DW category 2: muscularis propria with continuous
intermediate SI on DWI (lesion >1 cm, hyperintense on
DWI and hypointense on ADC, with low SI stalk and/or
low SI thickened inner layer on DWI, or broad-based/
sessile tumor with low/intermediate SI thickened inner
layer on DWI)3. DW category 3: lack of category 2 findings (lesions
corresponding to T2 category 3 findings) but with no
clear disruption of low SI muscularis propria.4. DW category 4: High SI tumor on DWI and low SI tumor
on ADC extending focally to muscularis propria.5. DW category 5: High SI tumor on DWI and low SI tumor
on ADC extending to the entire bladder wall and
extravesical fat.
3.2.5. Final scoring
A five-point VI-RADS score is generated using the individual
T2W, DWI, and DCE MRI categories and suggests the
probability of muscle invasion (Fig. 4, Supplementary Fig. 2,
and Table 2). The dominant sequences for risk estimates are
DWI (first) and DCE (second; especially if the DWI is
suboptimal). The T2 sequence is helpful as a first pass guide,
especially for categories 1–3:1. VI-RADS 1 (muscle invasion is highly unlikely): SC, CE,
and DW category 12. VI-RADS 2 (muscle invasion is unlikely to be present): SC,
CE, and DW category 2; both CE and DW category 2 with
SC category 33. VI-RADS 3 (the presence ofmuscle invasion is equivocal):
SC, CE, and DW category 3; SC category 3, CE or DW
category 3, the remaining sequence category 24. VI-RADS 4 (muscle invasion is likely): at least SC and/or
DWand CE category 4; the remaining category 3 or 4; SC
category 3 plus DW and/or CE category 4; SC category
5 plus DW and/or CE category 45. VI-RADS 5 (invasion of muscle and beyond the bladder is
very likely): at least SC plus DWand/or CE category 5; the
remaining category 4 or 5
The final score is firstly based on T2W imaging for the
morphology, because of their high spatial resolution in the
evaluation of the integrity of muscularis propria. The
presence of definitive muscular invasion is decided by
DWI and DCEMRI. If there is any discordance between T2W
and DCE sequences (a deviation of two categories between
T2W and DCE MRI), DWI improves the accuracy
[33,38,40,46] when the image quality of DWI sequence is
optimal.
3.3. Discussion: clinical Impact
3.3.1. Overview
MRI may be most promising in the pre-TURBT setting, given
that the tissue architecture has not been distorted by surgery
(ie, similar to preprostate biopsy). The current standard for
diagnosis and staging BC is TURBT [6]. Cystoscopy has
improved with enhanced intravesical imaging, such as
photodynamic diagnosis and narrow band imaging, and
better awareness of its importance in BC care [24]. However,
many tumors are understaged by TURBT or detrusor is
missing, and so complimentary improvements in imaging are
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and simultaneously stage a bladder tumor, such that a flexible
cystoscopymight be skipped and patients be taken directly to
TURBT. While histological confirmation remains the corner-
stone of BC diagnosis [28], this pathway might be faster than
reliance on TURBT [56]. For MRI to be a significant factor in
clinical care, it has to be reproducible and feasible in the
general hospital setting.
3.3.2. mpMRI and NMIBC
For NMI tumors, it is important to know the stage (pTa, pTIs,
and pT1) to help choose treatment. Of note, MRI is less
reliable at CIS detection. Of NMI cancers, accurate staging is
most vital for a T1 tumor. MRI could help inform tumor size
and likely stage, and help plan treatment. For example, for a
small T1 tumor with a clear stalk and no muscularis propria
involvement, a radical TURBT should be the goal and
intravesical BCG therapy could be initiatedwithout the need
for a re-TURBT. For a deeper invading T1 (T1b/c) tumor, with
no clear stalk or growth close to the muscularis propria, a
re-TUR should be mandatory and thought is given to
primary cystectomy [57,58]. Perhaps in the future, MRI with
anatomical and functional information could predict
tumors unlikely to respond to conservative therapy, for
which the primary approach should be more radical
[59]. Finally, knowing that approximately 25% of T1 tumors
are muscle invasive on re-TURBT, which obviously changes
therapeutic approach completely, accurate staging in T1
tumors might very well be one of the most important fields
for MRI in BC staging [19,60].
3.3.3. mpMRI and MIBC
For invasive, nonmetastatic BCs, there are different thera-
peutic strategies that can depend on the exact stage of the
tumor. For example, stage could be used to guide the
relative benefits from neoadjuvant chemotherapy [61]. For
bladder-sparing therapy and chemoradiation, MRI could
identify likely suitable tumors (unifocal, good bladder
capacity) and help plan a radical, complete TURBT [62].
3.3.4. mpMRI and treatment response
Although cystoscopy remains the standard means of post-
treatment follow-up, the need for frequent repeat exam-
inations has driven mpMRI applications as a noninvasive
alternative [63–65]. Data suggest qualitative and quantita-
tive DWI, and DCE MRI change has correlation to
pathological and clinical outcomes. This has potential
important use in predicting treatment sensitivity and
monitoring therapeutic response, particularly in patients
receiving neoadjuvant chemotherapy or radical chemor-
adiotherapy for muscle-invasive disease.
Post-treatment inflammation and fibrosis cause irregular
bladder wall thickening. This produces high SI on T2W
imaging, which makes it challenging to distinguish between
BC and benign treatment-related effects [15,66–68]. As a
result, the reported sensitivity, specificity, and accuracy of
T2W imaging to predict complete pathological response
following chemoradiotherapy are low (43%, 45%, and 44%,
respectively) [67]. Treatment-related effects can persist for upto 18–24 mo, so the timing of T2W imaging acquisition is
largely ineffectual in aiding judicious clinical decisionmaking
[68].
DCE MRI appears to successfully overcome the limita-
tions of distinguishing between treatment-related effects
and residual tumor following TURBT [69]. However, Wang
et al [50] demonstrated that DWI is superior to DCE MRI in
identifying tumor recurrence following either TURBT or
partial cystectomy. The reported accuracy, sensitivity,
specificity, and positive predictive values of DWI are 93%,
100%, 82%, and 89%, respectively, compared with 59%, 81%,
27%, and 54%, respectively, for DCE MRI.
Complete response following induction treatment is
associated with improved survival and informs candidate
selection for radical bladder preservation protocols [70–
76]. Widely investigated induction strategy employs TURBT
and neoadjuvant chemotherapy and chemoradiotherapy to
40 Gywith complete responders as identified on cystoscopy
and biopsy proceeding to a consolidative course of chemo-
radiotherapy to a total dose of 64–65 Gy [73,75]. Another
approach is assessing complete response following full-
dose chemoradiation to 64–60 Gy.
The feasibility of mpMRI to assess therapeutic response
to induction therapy was demonstrated by Yoshida et al
[67]. mpMRI performed after induction chemoradiotherapy
for T2–T4a N0M0 BC showed that DWI was significantly
superior in specificity (92%) and accuracy (80%) to both T2W
(45% and 44%) and DCE MRI (18% and 33%) in predicting
pathological response. All sequences however showed poor
sensitivity for detecting residual disease (43–57%).
Pretreatment DWI predicts sensitivity to induction
chemoradiotherapy. Treatment-sensitive bladder tumors
have significantly lower ADC values than chemoresistant
tumors (median 0.63  103 mm2/s vs 0.84  103 mm2/s;
p = 0.001) [77]. Considering other clinical variables such as
age, T stage, tumor size, tumor multifocality, presence of
carcinoma in situ, and hydronephrosis, only mean ADC was
identified as an independent predictor of chemoradiother-
apy sensitivity on multivariate analysis [77]. One explana-
tion for this is that tumor ADC correlates with cell cycle
regulators and molecular proliferative markers including
p53, p21, and Ki-67 [77–79].
The survival benefit of neoadjuvant chemotherapy is
recognized for those with MIBC [61,80,81]. On DCE MRI,
significant change from early to later enhancement following
three cycles of neoadjuvant chemotherapy is associated with
complete pathological response at cystectomy [41]. Persisting
early enhancement is indicative of poor chemotherapy
response [41,63]. Combining semiquantitative DCE MRI
parameters improves differentiation between residual blad-
der tumor and chemotherapy related effects with reported
sensitivity and specificity of 75% and 100%, respectively [41].
Neoadjuvant chemotherapy is not without toxicity.
Patients who do not respond are exposed to morbidity
and a delay in effective treatment [74]. Early mpMRI
scanning may offer opportunity to inform treatment
selection, with early response supporting continued use
or poor response supporting treatment switch. Nguyen et al
[65] used K-means cluster maps of DCE MRI to show that
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differentiate between responders and nonresponders to
neoadjuvant chemotherapy.
In patientswith advanced tumors, whomay receive up to
six cycles, prediction of overall response to chemotherapy
can be made with DCE MRI after two cycles with greater
sensitivity, specificity, and accuracy than conventional MRI
[63,64].
DWI has a role in assessing neoadjuvant chemotherapy
response. A significant increase in ADC frombaseline is seen
in those achieving complete pathological response com-
pared with incomplete responders and is associated with
improved overall survival and time to cystectomy
[82,83]. Example of a responder and nonresponder as seen
on DWI after three cycles of chemotherapy is shown in
Supplementary Fig. 3. DWI also provides predictive
information of neoadjuvant chemotherapy response, as
resistant bladder tumors appear to be more heterogeneous
in their spatial distribution of ADC [84].
Multiparametric MRI appears a promising tool to
monitor treatment response. However, the few currently
available reports either are small in size or have design
limitations. As such, mpMRI is not ready for standard care.
Current challenges include standardization of data acquisi-
tion and analysis, validation, and prospective testing within
clinical trials [85].4. Conclusions
Multiparametric MRI may improve the care of men with
prostate cancer through facilitating better diagnosis (by
targeting of the biopsy, avoiding biopsy, or identifying
missed cancers) and better treatment (by planning and
stratifying risk). The creation and updating of the Prostate
Imaging Reporting and Data System gave the foundations
for these improvements [86]. Here, we hope to have created
a foundation for mpMRI in BC staging, diagnosis, and
therapeutic response, through a consensus-driven ap-
proach to standardized imaging and reporting. We hope
that VI-RADS is user friendly, will allow simplified report-
ing, and in future years will be tested, validated, and refined
where necessary. While we do not advocate mpMRI for all
patients with BC, this imaging may compliment pathology
or reduce radiation-based imaging.
Endorsement of VI-RADS
VI-RADS has been endorsed as a reporting system for the
bladder by the Japanese Society of Abdominal Radiology,
European Association of Urology, and European Society of
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